Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.17) per share which missed the a

Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with

ALISO VIEJO, Calif.--(BUSINESS WIRE)--IHI Power Services Corp. (IPSC), a leading operator of power p

PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC)

US stock futures up, Dow futures gain 100+ points. Concentrix Corp (CNXC) shares down 24% after weak

Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected f

CNTY-813 is Century's potential iPSC-derived islet replacement therapy for T1D. CNTY-813 is engi

Advancing CNTY-813 as a potential functional cure in Type 1 Diabetes CNTY-813 iPSC-derived islet rep

U.S. stock futures rise, Nasdaq up 1%. Graham Corp shares down 8.7%. Other stocks declining in pre-m

Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries,

Top Wall Street analysts changed outlook on top names. See analyst ratings page for upgrades, downgr

Mizuho analyst Salim Syed initiates coverage on Century Therapeutics (NASDAQ:IPSC) with a Outperf

US stock futures higher, Lowe's shares fall after reporting earnings. Other stocks declining in

NORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP

Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.11) per share which beat the ana

PHILADELPHIA, May 13, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC),

Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), a biotechnology company developing induced

CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for pat

Century Therapeutics earns a speculative Buy rating, with a 10-15% upside and right-skewed return po

Wall Street analysts update ratings on top names. B of A Sec raised CMS Energy Corp's price targ

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Century Therapeutics (NASDAQ:IPSC) w

Other Events. On July 10, 2025, Century Therapeutics, Inc. (the "Company") filed with the Se

iSpecimen Inc. (NASDAQ:ISPC) (the "Company"), a leading provider of human biospecimens for r

Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.25) per share which beat the ana

Shares of Century Therapeutics, Inc. (NASDAQ: IPSC - Get Free Report) have been given an average rec

PHILADELPHIA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC)

Hikma Pharmaceuticals (OTCMKTS:HKMPF - Get Free Report) and Century Therapeutics (NASDAQ: IPSC - Get

The iPSC-derived NK cells clinical trial analysis report delivers important insights into ongoing re

Century Therapeutics is positioned as a leading contender in developing a durable, once-and-done cur

Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, whic

Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced

PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ('Century', NASDAQ: IPSC)

If you are looking for stocks that have gained strong momentum recently but are still trading at rea

If you are looking for stocks that have gained strong momentum recently but are still trading at rea

PHILADELPHIA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC)

Leerink Partners analyst Daina Graybosch downgrades Century Therapeutics (NASDAQ:IPSC) from Outpe

Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.40) per share which missed the a

PHILADELPHIA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC)

Chardan Capital analyst Geulah Livshits maintains Century Therapeutics (NASDAQ:IPSC) with a Buy a

Century Therapeutics (NASDAQ:IPSC) reported quarterly earnings of $0.89 per share which beat the ana

HC Wainwright & Co. analyst Mitchell Kapoor maintains Century Therapeutics (NASDAQ:IPSC) with